Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds in diagnostics and international markets.

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin guidance was cut. Learn more on ABT stock here.

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.